Favourable West Nile vaccine results
Friday, 27 February, 2009
Early results from a Phase I safety and efficacy trial of a West Nile virus vaccine, being developed by Acuvax’s US affiliate Hawaii Biotech, are “stunning”, the company said.
The results will enable an easier roll-out for a dengue fever vaccine, Acuvax’s CEO Dr William Ardrey said in a statement.
Hawaii Biotech, a private company in which Acuvax has a substantial shareholding, is trialling its vaccine in 24 healthy volunteers to check safety and antibody development.
All volunteers showed the presence of neutralizing antibodies. The vaccine is based on a proprietary recombinant DNA technology platform, which is being used by Hawaii to develop a vaccine for dengue fever, as well as candidates for malaria, tick-borne encephalitis virus and flu.
The company will now begin trials in children, the elderly and immuno-compromised patients.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
